BFRIMEDIUM SIGNALFINANCIAL10-K

BFRI shows improving profitability with meaningfully reduced losses despite increased R&D investment, while substantially drawing down inventory levels.

The company's loss reduction of approximately 41% alongside revenue growth of 12% suggests improving operational efficiency and market traction for its dermatological PDT products. However, the substantial increase in R&D spending and continued negative operating cash flow indicate the company remains in investment mode, requiring careful cash management.

Comparing 2026-03-19 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

BFRI demonstrated mixed but generally positive financial trends, with revenue growing modestly to $41.7M while net losses improved meaningfully from -$17.8M to -$10.5M. The company substantially reduced inventory levels from $6.6M to $1.4M, suggesting better demand forecasting or inventory management, though this coincided with deteriorating operating cash flow to -$13.4M. R&D expenses grew substantially to $3.7M, indicating continued investment in product development despite the company's loss position.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-80%
$10K→$2K

Capex reduced 80% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
-78.5%
$6.6M→$1.4M

Inventory drawn down 78.5% — strong sell-through or deliberate destocking; watch for supply constraints.

R&D Expense
P&L
+78%
$2.1M→$3.7M

R&D investment increased 78% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
+40.7%
-$17.8M→-$10.5M

Net income grew 40.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+34.1%
-$17.2M→-$11.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-30.1%
-$10.3M→-$13.4M

Operating cash flow fell 30.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
+29.2%
$22.1M→$28.6M

Asset base grew 29.2% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
-12.6%
$20.7M→$18.1M

Current assets declined 12.6% — monitor working capital adequacy and short-term liquidity.

Revenue
P&L
+11.7%
$37.3M→$41.7M

Revenue growing 11.7% — solid top-line momentum, watch margins for quality of growth.

SG&A Expense
P&L
+11.7%
$33.8M→$37.8M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-20
ADDED
As of March 16, 2026, there were 11,648,323 shares outstanding of the registrant s common stock, par value $ 0.001 per share.
TRADEMARKS, TRADE NAMES, AND SERVICE MARKS All trademarks, trade names, and service marks appearing in this Form 10-K are the property of their respective owners.
Solely for convenience, the trademarks and trade names in this Form 10-K are referred to without the symbols and , but such references should not be construed as any indication that their respective owners will not assert their rights thereto to the fullest extent under applicable law.
We do not intend to use or display other companies trademarks, trade names, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Business Overview We are a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy ( PDT ).
+7 more — sign up free →
REMOVED
As of March 19, 2025, there were 8,873,932 shares outstanding of the registrant s common stock, par value $ 0.001 per share.
References in this Form 10-K to Ferrer refer to Ferrer Internacional S.A.
References in this Form 10-K to Licensors refer collectively to Biofrontera Pharma, Biofrontera Bioscience and Ferrer.
References in this Form 10-K to Ameluz Licensor refer collectively to Biofrontera Pharma and Biofrontera Bioscience.
Business Overview We are a United States based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy ( PDT ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →